Krilogy Financial
RCKT icon

Krilogy Financial’s Rocket Pharmaceuticals RCKT Stock Holding History

Krilogy Financial’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-14,295
Closed -$48.9K – 1164
2026
Q2 		$48.9K Sell
14,295
-1,668
-10% -$5.55K ﹤0.01% 1037
2026
Q1 		$62.3K Buy
+15,963
New +$63.4K ﹤0.01% 943

Other funds holding RCKT

Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $755M AUM 11.28% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Krilogy Financial's RCKT Position: Q3 2026 in Review

Krilogy Financial sold out of Rocket Pharmaceuticals (RCKT) in Q3 2026, closing a stake of 14,295 shares — an estimated $48.9K sold.

Krilogy Financial first reported a position in RCKT in Q1 2026 and held it in 2 quarters. The position peaked at $62.3K in Q1 2026. 10 funds tracked by Wall St. Rank hold RCKT as of Q3 2026.

  • Krilogy Financial reported no remaining Rocket Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Krilogy Financial sold 14,295 Rocket Pharmaceuticals shares in Q3 2026, an estimated $48.9K.
  • Krilogy Financial first reported a position in Rocket Pharmaceuticals in Q1 2026 and held it in 2 quarters.
  • Krilogy Financial's Rocket Pharmaceuticals position peaked at $62.3K in Q1 2026.
  • 10 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2026.

Based on Krilogy Financial's 13F filing for Q3 2026, filed 13 Oct 2026.